The Valley Desk

NCT04385277 · Interventional trial

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Overall registry status Active not recruiting

Phase 2

Conditions Ganglioneuroblastoma, Nodular, Neuroblastoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov